The major cause of treatment failure in hematologic maligmetastatic tumors, the clinical field of cellular immunotherapy nancies is the development of resistance to chemotherapeutic has expanded rapidly.
the spleen. 14 The optimal conditions for both cytotoxic units. We then studied the possibility that the effector cell activity and preservation of hematopoiesis were reported in a activity of the IL-2-activated BMMC which is diminished after series of studies by these investigators.
15-18
removal of the IL-2 at 24 h could be recovered upon re-
The apparent non-cross-resistance between chemotheraexposure of the marrow to IL-2. We found that the optimum peutic and cellular mechanisms of tumor cell kill provide the conditions for preserving cytotoxicity were prolonged continurationale for the design of regimens to treat post-chemo- Ara-C and cloned in soft agar. The resulting cells were 15-NY, USA) with IL-2, 6000 IU/ml (Chiron Corporation, fold resistant to Ara-C and showed stable resistance in culture. Emeryville, CA, USA) or no IL-2 as a control, at a final cell HL60 leukemia cell clones resistant to daunomycin were concentration of 1.0 × 10 6 /ml and placed upright in a 37°C selected by similar methods and were greater than 50-fold humidified incubator with 5% CO 2 . At the end of 24 h of culresistant to daunomycin with increased mdr gene expression ture, the non-adherent cells were collected from the flasks by by Northern analysis. Daunomycin-resistant K562 cells, vigorous pipetting, pelleted by centrifugation at 400 g for kindly provided by Dr DA Gewirtz (Massey Cancer Center, 10 min and resuspended in a small volume of fresh CM. After University of Virginia, Richmond, VA, USA), were 15-fold cells were counted and viability determined by Trypan blue resistant to daunomycin, and K562/VP, which is 3 to 4-fold dye exclusion, aliquots were removed for cytotoxicity assay resistant to VP-16, was also tested as a target. (day 1), and the remaining cells were replaced in their original flasks at 1.0 × 10 6 /ml with fresh CM with or without IL-2 and incubated for an additional 7 days. Cytotoxic activity resulting LAK cell purging of tumor cell-contaminated human from replacement with fresh media ± IL-2 was then assayed bone marrow and preservation of hematopoietic (day 8 and day 15). activity Normal BMMC were mixed with 10% A549 lung cancer cells, Methylcellulose assay for BM colony formation MCF-7 breast cancer cells, or EM2 leukemia cells, or unstimulated PBMC as a control. Autologous donor PBMCs (generated Fresh BMMC from normal donors were plated in methylcelluin IL-2, 6000 IU/ml for 5 days) were added to this mixture at lose with hematopoietic growth factors (G-CSF + IL-3) at a 1:1 ratio with the BMMC. After 18 h of incubation, the cell 1 × 10 5 cells/well and CFU-C scored at 14-17 days. BMMC mixture was plated in methylcellulose for tumor cell outwere incubated for 24 h in CM plus or minus IL-2 (6000 growth and BM colony formation. IU/ml) before the addition of methylcellulose and growth factors. BMMC from normal donors were scored at 14-17 days for CFU-C.
Effector cell activity after limited IL-2 exposure and proliferative effect of IL-2 on BMMC Cytotoxicity assay
In order to test whether the progression to maximal antileukemic activity of effector cells induced in the marrow by IL-A standard 51 Cr release assay (CRA) was performed utilizing the NK-sensitive K562 cell line and the NK-resistant, LAK 2 activation would be diminished upon withdrawal of IL-2, fresh BMMCs from normal donors were incubated with IL-2, sensitive cell line Daudi as the target. Effector MC from each experimental condition were added to 10 000 51 Cr-labelled 6000 IU/ml, for 24 h and then washed to remove IL-2. The experimental groups, tested as effectors against labeled Daudi target cells at effector:target ratios of 40, 10 or 2.5:1 in a final volume of 200 l/ well in 96-well V-bottom plates (Elkay Labtargets were: A-8: BMMC exposed to IL-2 for 24 h followed by medium free of IL-2 for 7 days and CRA performed at day systems, Shrewsbury, MA, USA). Control wells contained target cells in media (spontaneous release) and target cells in 2% 8; A-8c: BMMC tested at day 8 following incubation for the entire 8-day period in the presence of IL-2; B-15: BMMC SDS (maximum lysis). Plates were then centrifuged at 200 g exposed to IL-2 for 24 h, medium without IL-2 for 7 days and was lower than that of the sensitive controls, but the daunomycin-resistant HL60 cells were more sensitive to LAK killing subsequent re-exposure to IL-2 days 8-15 and testing in CRA at day 15; B15c: BMMC cells were incubated in the presence than the chemosensitive controls. VP16-resistant K562 cells were also more sensitive than their drug-sensitive counterparts of IL-2 for the entire 15-day interval prior to the CRA.
in three of four pairs.
Statistical methods Activation of human bone marrow effectors by IL-2: effect on CFU-C and cytotoxicity against tumor targets
All sets of paired samples were compared by Wilcoxon signed-rank test on the maximum, minimum and median of differences. Table 2 shows the results from eight separate donor marrows assayed fresh or following 24 h incubation in medium with or without IL-2. We found no significant loss of CFU-C from marrow incubated in medium for 24 h or marrow incubated in Results IL-2 for 24 h (P = 0.69 and P = 0.30, respectively, for the two experimental conditions vs control unincubated marrow).
LAK cell purging of tumor cell-contaminated human bone marrow and preservation of hematopoietic Cytotoxicity of 24-h-activated BM against the LAK sensitive Daudi cell line is shown in Table 3 . These results revealed a activity significant enhancement of cytolytic activity by incubation in IL-2 vs medium for 24 h (P = 0.016 by exact nonparametric LAK cells mediated a reduction in tumor cell growth (greater than 90% reduction in EM-2 colony number; disappearance
Wilcoxon signed-rank test). of A549 cells and MCF-7 cells), whereas control PBMC (no IL-2 treatment) co-culture resulted in overgrowth of the plate by malignant cells within bone marrow. In these co-cultures Persistence of effector cell activity after limited Il-2 exposure and proliferative effect of IL-2 on BMMC with LAK cells, there was minimal loss of CFU-C in comparison with control marrow cultures without added LAK cells (25% loss at 1:1 and 3% loss at 1:10 ratios of LAK:BMMC,
The results of these assays are shown in Table 4 . as shown in columns A-8 and A-8c of Table 4 , there was a marked respectively). BFU-E colonies were reduced 41% and 24% at these ratios of LAK:BMMC (data not shown).
increase in the cytotoxicity of cells incubated continuously in IL-2 for 8 days over controls exposed for 24 h and followed by withdrawal of IL-2 (P = 0.0002 by Wilcoxon signed-rank test). Likewise, 15-day exposure to IL-2 yielded slightly greater
Immunologic sensitivity of chemo-resistant tumor targets cytotoxicity than 8-day exposure (columns B-15c vs A-8c, P = 0.01). However, the degree of cytotoxicity achieved by a 15-day continuous exposure was not significantly different The effect of LAK cells on chemotherapy-resistant tumor cells was studied using leukemia cell lines selected for resistance from that of a 24-h exposure followed 7 days later by a 7-day re-exposure (B15c vs B15, P = 0.91), demonstrating the ability to the two major drugs utilized in the treatment of leukemia (Ara-C and anthracyclines). The results of cytotoxicity assays of cells exposed briefly to IL-2 to 'recapture' the effect of continuous exposure despite an interval without IL-2. If the of normal donor peripheral blood-derived LAK cells against chemotherapy-sensitive and resistant tumor cell lines are BMMC were not exposed to IL-2 for the initial 24-h activation, there was no detectable cytotoxicity after 8 days of incubation shown in Table 1 . Ara-C-resistant K562 cells were significantly more sensitive to LAK effectors than were chemosensiin CM; thus, in the absence of the initial 24-h exposure, no cytotoxicity resulted if the 7 days continuous IL-2 exposure tive controls (P = 0.008 by the Wilcoxon signed-rank test for the eight experimental pairs, representing the target cell line were delayed until days 8-15. In all cases in which the BMMC were initially exposed to in continuous culture and effectors from eight different patients). The sensitivity of daunomycin resistant K562 cells IL-2 (ABM/medium, ABM/IL-2), the recovery of viable cells for 
Table 4
Recovery of cytotoxic activity of BMMC after interruption Table 3 Cytotoxicity by medium without IL-2 for 7 days, the mean recovery was 109% (range 101-127%), and in the presence of continuous A8 effectors are BMMC-exposed to IL-2 for 24 h followed by IL-2, 119% (range 100-152%), suggesting that even limited medium free of IL-2 for 7 days and CRA performed at day 8; A8c effectors are BMMC effectors tested at day 8 following incubation exposure to IL-2 could directly or indirectly (via induced for the entire 8-day period in the presence of IL-2. B15 refers to cytokines) stimulate cell proliferation or at least maintain cell BMMC exposed to IL-2 for 24 h, medium without IL-2 for 7 days numbers and viability (data not shown).
and subsequent re-exposure to IL-2 days 8-15 and testing in CRA
Our pooled experimental results demonstrate that there is at day 15; B15c cells were incubated in the presence of IL-2 for no loss of cytotoxicity when IL-2 exposure is interrupted for the entire 15-day interval prior to the CRA.
1 week followed by re-exposure to IL-2 and that there is a modest proliferative effect of the IL-2 on BMMC. sitivity of selected tumor cell lines to LAK-mediated cytotoxicity and showed that bone marrow contaminated with several different tumor cell lines could be purged by the addition of Discussion PBMC-derived LAK cells without loss of hematopoietic precursor activity. Our experiments demonstrate that the bone marrow is a source of effector cells with potent antitumor activity attribuOur next objective was to test the sensitivity of selected chemotherapy-sensitive and resistant cell lines to cellular table to IL-2-induced proliferation and activation of cytotoxic NK and/or T cell precursors. In our initial experiments, we cytotoxicity. We demonstrated, using sensitive cell lines and their counterparts selected for resistance to Ara-C, daunomyused peripheral blood-derived MNCs to demonstrate the sen-cin and VP16, that the development of resistance to these upon restimulation over the succeeding 7 days surpasses that of a continuous 8-day exposure and is comparable to that of pharmacologic agents did not confer resistance to PBMCderived LAK cell cytotoxicity. Thus, the use of IL-2 to stimulate a continuous 15-day exposure. These results suggest that marrow effector cell viability and cytotoxicity do not demonstrate a population of bone marrow-derived cytotoxic effectors with antileukemic activity should be equally effective against the a strict dependence on the continuous exposure to IL-2, a finding which is of importance in the design of therapeutic chemotherapy-resistant residual leukemic cells which are present in the bone marrow of most patients in hematologic trials.
We also demonstrated the preservation of hematopoietic remission. Other investigators have reported results consistent with our own regarding the cytotoxicity of human LAK cells reconstitutive activity after IL-2 treatment of the BMMC, a finding which was in agreement with observations from other against malignant cells of hematologic origin.
5,21-25 The cytotoxicity of autologous LAK cells against chemotherapy-resistlaboratories. 18 ,32-34
The use of IL-2 as an immunotherapeutic adjunct to autoant target cells is the most important requirement for the exploration of this approach in the therapy of minimal residual logous bone marrow or stem cell transplant for hematologic malignancy has been under investigation for several years, disease. Our data, along with other observations demonstrating comparable LAK sensitivity for chemosensitive and resistwith phase III trials now underway. Preclinical and pilot clinical data support several different approaches to ex vivo actiant targets 26 provide the basis for a clinical protocol using IL-2-incubated BMMC for aBMT patients with acute leukemia vation of the hematopoietic product, including long-term culture of noncryopreserved BMMC or PBMC in IL-2 during the in remission.
The possibility that IL-2 stimulates the growth of leukemic patient's conditioning regimen, 24, 35 or the administration of IL-2 to patients post aBMT with or without LAK cells after hemablasts has been studied by two groups, with the majority of data supporting the lack of significant stimulation of blast cell tologic reconstitution. 36 The potential role of other immunomodulatory cytokines also remains to be explored. The selecproliferation by IL-2.
9,27 Although the mechanisms of IL-2 activity may involve direct effects on leukemic blasts, an tion of the optimal regimen will await the results of carefully designed clinical trials which incorporate laboratory correimmunologically mediated effect is more likely. Olive et al 28 recently reported that IL-2 exposure caused an increase in the lates to define further and improve the essential components of this therapy. expression of CD54/ICAM-1 and CD58/LFA-3 molecules or myeloid and lymphoid blasts, an observation which supports the likelihood that T and/or NK cell interaction with these targets occurs via adhesion molecule-ligand-mediated Acknowledgement interactions.
The importance of treating the BMMC product in vitro folThis work was supported in party by the William Myers Research Fund. lowed by continued exposure of the product and the patient to IL-2 in vivo was suggested by the data of Mazumder et al, [14] [15] [16] [17] [18] who showed in a murine model that both components were required for optimal antitumor activity. The murine data limited by its multisystem toxicities. 32 The optimal require- an initial 24-h exposure, the level of cytotoxicity achieved
